Analyst Reco. Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:19:39 08/06/2026 BST			5-day change	1st Jan Change
73.46 ^USD	+0.50%		-3.28%	+9.55%

05-27	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	CI
05-26	Arrowhead Pharmaceuticals Presents New Positive Clinical Data for Plozasiran at the 94th European Atherosclerosis Society Congress	CI

Analyst Reco.

05-08	RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating	MT
05-01	JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target	MT
04-21	Morgan Stanley Upgrades Arrowhead Pharmaceuticals to Overweight From Equal Weight, Adjusts PT to $100 From $78	MT
01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
11-19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
22/10/25	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
08/10/25	RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk	MT
08/08/25	RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk	MT
14/05/25	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	MT
13/05/25	RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	MT
14/02/25	B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating	MT
12/12/24	B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating	MT
03/12/24	HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	MT
05/07/24	HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	MT
10/05/24	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	MT
08/02/24	B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	MT
07/02/24	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	MT
04/12/23	BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	MT
04/12/23	B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	MT
30/11/23	Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	MT
21/07/23	TD Cowen Starts Arrowhead Pharmaceuticals at Outperform	MT
02/06/23	Piper Sandler Adjusts Price Target on Arrowhead Pharmaceuticals to $59 From $52, Maintains Overweight Rating	MT